Causaly secures $60M to advance AI-driven drug discovery

Date:

London and San Francisco-based drug discovery AI startup, Causaly, has secured $60m in a series B funding round led by ICONIQ Growth. The funding will be used to expand the company’s presence in the US. Causaly utilises a combination of generative AI solutions and a best-in-class knowledge graph to enable biomedical researchers to rapidly synthesise and reference thousands of published research papers. The company claims its software can offer a 10x productivity gain for researchers, taking research that usually requires two-to-three years and completing it in two-to-three weeks. It hopes to use these methods to identify new treatments for diseases including Parkinson’s and multiple sclerosis.

See also  Modular Raises $100M Funding to Fuel AI Startup Growth

Frequently Asked Questions (FAQs) Related to the Above News

What is Causaly?

Causaly is a drug discovery AI startup that uses generative AI solutions and a knowledge graph to help biomedical researchers synthesize and reference thousands of research papers quickly.

How much funding has Causaly secured in its latest funding round?

Causaly has secured $60 million in a series B funding round led by ICONIQ Growth.

What will the funding be used for?

The funding will be used to expand Causaly's presence in the US.

How does Causaly's software benefit researchers?

Causaly claims that its software can provide a 10x productivity gain for researchers. It can complete research that typically takes two to three years in just two to three weeks.

What is Causaly's goal in using AI in drug discovery?

Causaly aims to use AI methods to identify new treatments for diseases such as Parkinson's and multiple sclerosis.

Where is Causaly based?

Causaly is based in both London and San Francisco.

Which company led the series B funding round for Causaly?

The series B funding round for Causaly was led by ICONIQ Growth.

What are the main technologies Causaly utilizes for its drug discovery process?

Causaly uses generative AI solutions and a best-in-class knowledge graph to facilitate its drug discovery process.

What is the potential impact of Causaly's software on the medical research field?

Causaly's software has the potential to greatly accelerate the research process, allowing for faster identification of new treatments and advancements in biomedical research.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Advait Gupta
Advait Gupta
Advait is our expert writer and manager for the Artificial Intelligence category. His passion for AI research and its advancements drives him to deliver in-depth articles that explore the frontiers of this rapidly evolving field. Advait's articles delve into the latest breakthroughs, trends, and ethical considerations, keeping readers at the forefront of AI knowledge.

Share post:

Subscribe

Popular

More like this
Related

Canada Boosts Arctic Defence Amid Climate Change Threats

Canada ramps up Arctic defense amid climate change threats with new policy, Arctic-compatible vehicles, and potential nuclear submarines.

OpenAI CEO Sam Altman Joins Billionaire Club, Trails Behind Elon Musk

OpenAI CEO Sam Altman now a billionaire, but still trails behind Elon Musk in tech industry dominance.

Smart Ways Retirees Can Maximize Social Security Checks

Discover 7 smart ways retirees can maximize their Social Security checks, from covering essentials to investing for the future.

Generative AI Surge: ChatGPT Revolutionizes Workplace Dynamics

Discover how ChatGPT is revolutionizing workplace dynamics among younger employees. Explore the rising trend of generative AI tools in the workplace.